MEDIFIRST SOLUTIONS ANNOUNCES UPDATE
ON INTERNATIONAL SALES
November 21 2016 - 10:58AM
InvestorsHub NewsWire
Freehold, NJ – November 21, 2016 –InvestorsHub
Newswire-- MEDIFIRST SOLUTIONS, INC. (OTCQB:
MFST) (the “Company” or “Medifirst”) A provider of innovative
laser technology with its FDA 510(k) cleared Infrared Time Machine
TTML-8102000 Laser Thermal Therapeutic Device would like to update
its shareholders on its progress in the international market. The
Company has previously announced that it has met with medical
representatives and buyers in Dubai, Saudi Arabia, Kuwait, Qatar,
Morocco and Spain. Medifirst is pleased to announce that it has
been asked to bring it medical staff to Morocco and Dubai to
demonstrate its laser technology as part of finalizing its first
international sales orders. The Company is optimistic that it will
have firm commitments for bulk orders once the demonstrations are
completed. Commented CEO Bruce J. Schoengood, “We are thrilled with
the response to our lasers by the international community and we
are excited to complete the demonstrations, meet our new vendors,
complete and fulfill our purchase orders and finalize our new
distribution agreements. We are eager to have our Medical Director
and staff show how effective our lasers are in reducing pain.” The
Company has scheduled the demonstrations in January and anticipates
that it will, as previously announced, begin booking sales in Q1
2017. Continued Schoengood, “As we continue to set up
international operations, we will also be training licensed
technicians to use the laser so as to expedite sales in the
Mid-East, Spain and Africa.”
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket
Notification 510(k) submission for “The Time Machine” Series Laser,
received clearance from the U.S. Food and Drug Administration
(“FDA”) to market its infrared Time Machine TTML-8102000 Laser
Thermal Therapeutic Device. The Time Machine Series Lasers Model
TTML-8102000 - 810/830nm is intended for use in temporary relief of
minor muscle and joint pain, stiffness, minor arthritis pain,
muscle spasm, temporary increase in local blood circulation and
temporary relaxation of muscles by means of topical elevated tissue
temperature from infrared spectral emissions. Due to the
decrease of inflammation, patients have seen immediate aesthetic
improvements as well, such as in scar and incision healing. The
hand-held laser device, with pin-point accuracy, often gives
patients immediate results with no redness, swelling or down-time.
This unique laser device offers medical professionals an affordable
and effective tool to enhance their treatment protocols for their
patients and provide new revenue streams for their practice. The
laser division will be operated out of Medifirst's wholly owned
subsidiary, Medical Lasers Manufacturer. Visit
www.medifirstsolutions.com for more information.
Forward-Looking Statements:
The statements in this press release that relate to the company's
expectations with regard to the future impact on the company's
results from new products in development are forward-looking
statements, and may involve risks and uncertainties, some of which
are beyond our control. Such risks and uncertainties are
described in greater detail in our filings with the U.S. Securities
and Exchange Commission. Since the information in this press
release may contain statements that involve risk and uncertainties
and are subject to change at any time, the company's actual results
may differ materially from expected results. We make no
commitment to disclose any subsequent revisions to forward-looking
statements. This release does not constitute an offer to sell or a
solicitation of offers to buy any securities of any entity.